Werewolf Therapeutics (NASDAQ:HOWL) Receives “Buy” Rating from HC Wainwright

Werewolf Therapeutics (NASDAQ:HOWL)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a report released on Friday, Benzinga reports. They currently have a $15.00 price target on the stock.

Separately, Wedbush assumed coverage on Werewolf Therapeutics in a report on Wednesday, August 23rd. They set an “outperform” rating and a $9.00 price objective on the stock.

Werewolf Therapeutics Price Performance

NASDAQ:HOWL traded down $0.10 during trading hours on Friday, reaching $2.47. 6,621 shares of the company’s stock were exchanged, compared to its average volume of 133,975. The business’s 50-day simple moving average is $2.84 and its two-hundred day simple moving average is $2.78. The company has a market capitalization of $88.08 million, a P/E ratio of -2.00 and a beta of 0.13. Werewolf Therapeutics has a 12 month low of $1.39 and a 12 month high of $6.03. The company has a quick ratio of 9.82, a current ratio of 9.82 and a debt-to-equity ratio of 0.33.

Werewolf Therapeutics (NASDAQ:HOWL) last released its earnings results on Thursday, August 10th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.27. Werewolf Therapeutics had a negative return on equity of 33.23% and a negative net margin of 165.15%. The firm had revenue of $8.08 million for the quarter, compared to analyst estimates of $3.05 million. Sell-side analysts expect that Werewolf Therapeutics will post -1.16 EPS for the current fiscal year.

Institutional Trading of Werewolf Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Bank of America Corp DE raised its holdings in Werewolf Therapeutics by 43,994.1% in the 4th quarter. Bank of America Corp DE now owns 1,533,592 shares of the company’s stock valued at $3,144,000 after buying an additional 1,530,114 shares during the last quarter. Millennium Management LLC grew its stake in shares of Werewolf Therapeutics by 63.9% in the 4th quarter. Millennium Management LLC now owns 838,302 shares of the company’s stock valued at $1,719,000 after buying an additional 326,694 shares during the period. Schonfeld Strategic Advisors LLC raised its holdings in Werewolf Therapeutics by 345.0% during the second quarter. Schonfeld Strategic Advisors LLC now owns 326,702 shares of the company’s stock worth $996,000 after buying an additional 253,284 shares during the last quarter. Alyeska Investment Group L.P. increased its stake in Werewolf Therapeutics by 92.9% in the 1st quarter. Alyeska Investment Group L.P. now owns 397,808 shares of the company’s stock valued at $1,034,000 after buying an additional 191,607 shares during the last quarter. Finally, Tejara Capital Ltd purchased a new stake in Werewolf Therapeutics in the 4th quarter valued at about $264,000. 67.44% of the stock is currently owned by institutional investors.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.